The Federal Council of Medicine (CFM) published, on 10/14/2022, CFM Resolution No. 2,324/22, which authorizes the use of cannabidiol (CBD) for treatment … CFM updates its Resolution on cannabidiol prescription and use

ANVISA published, in the Federal Official Gazette, RDC No. 751/2022, which provides and defines, in relation to medical devices, the (i) risk classification rules; (ii) labeling … ANVISA approves new Resolution RDC related to Medical Devices

The new generations of products are the result of the increasing combination of different technologies, leading to a crossing of borders between … Combined products in Brazil – brief comments on Anvisa’s (Brazilian National Health Surveillance Agency) current understanding

The Ministry of Health (MH) sent Brazilian National Health Surveillance Agency (Anvisa) a request for exemption from the sanitary registration, on an … Brazilian National Health Surveillance Agency authorizes exceptional drug and vaccine use against Monkeypox by the Ministry of Health

On August 8th, 2022, during the 12th Extraordinary Public Meeting of DICOL, ANVISA’s Collegiate Board of Directors announced the completion of the toxicological … Brazilian National Health Surveillance Agency (ANVISA) decides to ban Carbendazim

In December 2019, ANVISA started the process of toxicological revaluation of the Active Ingredient (AI) Carbendazim, as signs of toxicity were identified … Carbendazim toxicological revaluation about to be completed by ANVISA